[A25-20] Isatuximab (multiple myeloma, first line, combination with bortezomib, lenalidomide and dexamethasone) – Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2025
Project no.:
A25-20
Commission:
Commission awarded on 11.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Result of dossier assessment:
Hint of minor added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-20
| Project no. | Title | Status |
|---|---|---|
| A21-61 | Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide und dexamethasone) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-60 | Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V | Commission completed |